TickerTalks
Browse all tickers →
TickerTalks›$WHWK
WHWHWK

Whitehawk Therapeutics Inc

$WHWK·$213M·Biotechnology·Healthcare
$3.04+2.4%YTD+58.5%1Y+44.8%
Price updated 9h ago·X counts updated 4d ago
WHWHWK
$WHWKWhitehawk Therapeutics Inc
$3.04+2.36%1 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $WHWK on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

1X posts · last 7 days
Sep 28Oct 11
Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-05-20

Whitehawk Therapeutics (formerly Aadi) is bullish on a financing catalyst, popping about 15% premarket after announcing an $87.5M private-placement equity raise, its second large PIPE on the name. Bulls frame it as smart-money validation (what the pros paid), arguing good antibody-drug-conjugate (ADC) assets are hard to come by now that most public ADC names have been acquired, making ADCs the place to be again. The doubled institutional interest across two placements is treated as the key bullish signal for the small-cap biotech.

Read what X is saying about $WHWK

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $WHWK — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-10-02

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Whitehawk (formerly Aadi) just announced an $87.5M PIPE — second large financing by smart money.

Whitehawk Therapeutics (formerly Aadi) is a clinical-stage ADC biotech. The business just announced its second large PIPE financing, which bulls frame as smart-money validation.

  • The business is pre-revenue: PS 0, PE -2.5, ROIC -106% — standard clinical-stage biotech P&L; the thesis is pipeline progression plus financing dynamics.
  • The financing signal is specific: $87.5M private-placement equity raise, second large PIPE on the name — a tangible institutional validation of the ADC program.
  • 52-week range position is 52% with vol at 66% of average — mid-range on quiet volume, with the stock up 15% premarket on the raise announcement.

Nov 5 Q3 is the gate — any ADC pipeline update plus cash runway confirmation extends the stock. A clinical disappointment or no new pipeline data and the stock stays range-bound.

Agrees with X sentimentThe thread has substantive drivers — specific $87.5M PIPE as a second large financing, smart-money-validation framing on ADC program, premarket +15% reaction — all grounded.

What to watch: Nov 5 Q3 — ADC pipeline updates, cash runway, operating-loss trajectory, and any partnership commentary. A clinical disappointment is the hard invalidator.

On the calendar: 2026-11-05 — Q3 earnings

Read the AI verdict on $WHWK

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing precision therapies for genetically-defined cancers with no currently approved treatments.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $WHWK.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $WHWK

Neutral — Clinical-stage biotech developing precision therapies for genetically-defined cancers with no currently approved treatments.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+35.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-106%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-47.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-79.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.20$-0.30+32.4%
Q1 2026May 7, 2026$-0.32$-0.36+11.1%
Q4 2025Mar 12, 2026$-0.34$-0.55+38.2%
Q3 2025Nov 6, 2025$-0.26$-0.51+49.0%
Next earningsThu, Nov 5·consensus EPS $-0.26

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0-100.0%——$-0.32—
Q4 FY25$0-100.0%——$-0.34$-17.2M
Q3 FY25$0-100.0%——$-0.26$-15.4M
Q2 FY25$0-100.0%——$-0.76$-53.0M

Forward consensus

5-year forecast · up to 8 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$8.8M$8.8M – $8.8M-$0.94-$1.17 – -$0.738
FY27$10.9M$10.9M – $10.9M-$0.88-$0.94 – -$0.767
FY28$13.5M$13.5M – $13.5M-$0.80-$1.09 – -$0.486
FY29$16.7M$16.7M – $16.7M-$0.84-$0.84 – -$0.844
FY30$20.6M$20.6M – $20.6M-$0.87-$0.87 – -$0.873

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.30%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-27.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-20.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 26 other (26 awards) in window

See when $WHWK insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsSep 113
AI summary

Vijay K. Iyengar filed an initial Form 3 (Initial Statement of Beneficial Ownership) as a newly appointed Director of Whitehawk Therapeutics, Inc. on September 9, 2026. No securities of any class are beneficially owned by the reporting person. Routine new-director disclosure with no equity position reported.

8-KOfficer or director changeSep 108-K — Item 5.02: Officer or director change
AI summary

Whitehawk Therapeutics expanded its board from 9 to 10 directors and appointed Vijay Iyengar, M.D. (age 54) as Class III director effective September 9, 2026, serving through the 2029 annual meeting. Iyengar previously served as EVP of Global Medical Affairs at Incyte Corporation (2022–2025) and EVP of Global Strategy at a prior biopharma (2016–2022). His clinical and medical affairs expertise strengthens Whitehawk's board oversight of its therapeutic pipeline development.

8-KShareholder voteJun 128-K — Item 5.07: Shareholder vote
AI summary

Whitehawk Therapeutics held its 2026 Annual Meeting on June 11, 2026 with approximately 82% of voting power present. Shareholders elected Behzad Aghazadeh PhD, Richard Maroun, and Emma Reeve as Class III directors through 2029; approved advisory executive compensation; and ratified BDO USA P.C. as independent auditor. Routine governance meeting with no material contested outcomes.

S-3Shelf registrationMay 29S-3
AI summary

Whitehawk Therapeutics, Inc. filed a Form S-3 shelf registration statement on May 29, 2026 for resale of shares by selling stockholders on a delayed or continuous basis under Rule 415. The filing names selling stockholders but the total dollar amount is not stated in the available excerpt. This is a resale shelf for existing shareholders rather than new primary-share dilution from the company, though it enables selling shareholders to liquidate their positions over time.

SC 13D/AActivist amendmentMay 18SC 13D/A
AI summary

Acuta Capital Partners, LLC and its managing partner Anupam Dalal filed Amendment No. 2 to Schedule 13D for Whitehawk Therapeutics, Inc. (WHWK), reporting Acuta's beneficial ownership of 4,685,912 shares (8.7%) with shared voting/dispositive power, and Dalal's combined position of 4,843,775 shares (9.0%) including 157,863 directly held. The share count of 53,783,329 reflects the May 14, 2026 closing of a private placement. Acuta Capital filed a 13D (not passive 13G), suggesting potential active investor engagement with Whitehawk Therapeutics.

SC 13D/AActivist amendmentMay 14SC 13D/A
AI summary

Avoro Capital Advisors LLC filed an amended Schedule 13D on WHWK disclosing beneficial ownership (15,893,516.00 shares) as of 2026-05-14. The filer's stated intent is passive investment with no plan to influence control of the company.

8-KMaterial agreementMay 138-K — Item 1.01: Material agreement · Item 3.02: Unregistered equity sale · Item 7.01: Press release / Reg FD
AI summary

WHWK entered into a purchase agreement (8-K Item 1.01, dated 2026-05-13). Size: approximately $87,500,000. Material definitive agreement — investors should review the full exhibit for covenants, conditions, and use of proceeds.

+ 13 other (2 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Surrozen (NASDAQ:SRZN) & Whitehawk Therapeutics (NASDAQ:WHWK) Financial Comparisondefenseworld.net·4d agoWhitehawk Therapeutics, Inc. (NASDAQ:WHWK) Stock Has Consensus Target Price of $8.33 According to Brokeragesdefenseworld.net·8d agoWhitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026prnewswire.com·15d agoAnalysts Set Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Price Target at $8.20defenseworld.net·30d agoWhitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com·31d ago

In themes

Explore the broader themes this ticker is being talked about under.

Trending on X

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · last 7 days

No standout posts about $WHWK on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport